CERS – $2,200 Short Sale

Short selling CERS Stock on Positive Phase 3 Clinical Results.

CERS (Cerus Corporation) moved today on huge volume because of positive phase 3 trial results. This PR release shows promise for their leading drug making it to market, however, they have a struggling balance sheet, and a $70M at the money offering in the works. This toxic financing stifled any big runs, and caused the crash that we were able to short sell into.